Literature DB >> 2013615

Active production of anti-human T-lymphotropic virus type I (HTLV-I) IgM antibody in HTLV-I-associated myelopathy.

K Nagasato1, T Nakamura, K Ohishi, K Shibayama, M Motomura, K Ichinose, M Tsujihata, S Nagataki.   

Abstract

We investigated the presence of anti-human T-lymphotropic virus type I (HTLV-I) IgM in sera and cerebrospinal fluid from patients with HTLV-I-associated myelopathy (HAM) by Western blot analysis. Analyses of 36 serum samples revealed that most patients (31/36; 86.1%) had anti-HTLV-I IgM, whereas only four of 23 (17.4%) HTLV-I carriers had it. In studies of cerebrospinal fluid, anti-HTLV-I IgM was detected in 24 of 36 (66.7%) HAM patients, whereas none was detected in nine HTLV-I carriers. The differences were statistically significant (p less than 0.01). These results suggest that persistent active replication of HTLV-I occurs in the central nervous system as well as in the peripheral blood of HAM patients, and may contribute to the development of HAM.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013615     DOI: 10.1016/0165-5728(91)90002-o

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  Increased number of circulating HTLV-1 infected cells in peripheral blood mononuclear cells of HTLV-1 uveitis patients: a quantitative polymerase chain reaction study.

Authors:  A Ono; M Mochizuki; K Yamaguchi; N Miyata; T Watanabe
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

2.  Visualization of HTLV-1-specific cytotoxic T lymphocytes in the spinal cords of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Eiji Matsuura; Ryuji Kubota; Yuetsu Tanaka; Hiroshi Takashima; Shuji Izumo
Journal:  J Neuropathol Exp Neurol       Date:  2015-01       Impact factor: 3.685

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.